Skip to content

Abstract 8050: Sodium-Glucose Cotransporter-2 Inhibitors Increase Estimated Glomerular Filtration Rate Slope and Ameliorate Clinical Outcomes After Catheter Ablation in Atrial Fibrillation Patients with Heart Failure

Nov 2026 · Circulation · 0 citations

Abstract

Background: Treatment of sodium-glucose cotransporter 2 inhibitors (SGLT2is) has been demonstrated to decrease cardiovascular events in patients with heart failure (HF) regardless of ejection fraction. Moreover, SGLT2i treatment also prevented deterioration of renal function in those with chronic kidney disease (CKD). Atrial fibrillation (AF) develops HF and CKD, and vice versa. Hypothesis: we hypothesized that the cardiorenal effect of SGLT2i might improve the clinical outcomes in persistent AF (PeAF) patients with HF who underwent catheter ablation. Methods: PeAF patients with HF (N-terminal prohormone of brain natriuretic peptide, NT-proBNP ≥400 pg/ml) undergoing index pulmonary vein isolation were prospectively enrolled (n=200). After screening, eligible patients were alternatively allocated to two parallel groups at random before the procedure: Group SGLT2i[+] was to receive SGLT2is (empagliflozin 10mg QD or dapagliflozin 10mg QD) for ≥1 month prior to catheter ablation and were continued during follow-up (n=100); Group SGLT2i[-] was not to receive the SGLT2is (n=100). During the follow-up, blood test and ECG recordings were regularly performed at baseline (before the procedure) and at 1, 3, 6, 9, and 12 months after the procedure. 24-hour and 1-week Holter ECG recordings were performed at 6 and 12 months, respectively. The event-free rate of 1-year atrial-arrhythmia recurrence (AR) was compared between SGLT2i[+] and SGLT2i[-]. eGFR slope was calculated using linear regression analysis and was related to AR. Results: There was no significant difference in patient/procedure characteristics between SGLT2i[+] and SGLT2i[-]. The serum NT-proBNP levels at the enrollment were unchanged between the two groups but SGLT2i[+] had significantly lower NT-proBNP levels at 1 month than SGLT2i[-]. Kaplan-Meier analysis demonstrated that SGLT2i[+] had significantly higher event-free rate of 1-year AR than SGLT2i[-] (91%* vs. 77%, *p<0.05, Figure 1). eGFR at baseline was unchanged between SGLT2i[+] and SGLT2i[-] (65±20 ml/min/1.73m 2 and 69±20 ml/min/1.73m 2 ). Compared to the baseline, eGFR was initially decreased at 1 month in both SGLT2i[+] and SGLT2i[-] (ΔeGFR: -5.1±13.6 ml/min/1.73m 2 and -6.5±13.4 ml/min/1.73m 2 ). After 1 month, SGLT2i[+] had larger ΔeGFR (ΔeGFR: 2.4±10.2 ml/min/1.73m 2 * and -1.9±13.4 ml/min/1.73m 2 ) and had greater eGFR slope values (0.25±0.09* and -0.23±0.12) than SGLT2i[-] during the 1-year follow-up (Figure 2 and 3). Patients without 1-year AR showed greater eGFR slope values than those with 1-year AR (0.11±0.08* and -0.31±0.17, Figure 3). Conclusion: Periprocedural SGLT2i treatment decreased AR during 1-year follow-up in AF patients with HF undergoing catheter ablation. We first demonstrated that the favorable outcomes by SGLT2i might, at least partly, be associated with the amelioration of HF and renal function by its cardiorenal effect.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.